Biotech · Private company · Palo Alto, CA, US
Riboscience, LLC.
Track this companyFree. Adds Riboscience, LLC. to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- RBS2418Phase 2 · Advanced Unresectable Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- RBS2418Phase 2 · Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- STRIDE (durvalumab + tremelimumab)Phase 2 · Advanced Unresectable Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Other approved anti-cancer therapyPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- RBS2418Phase 1 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaPHASE2 · RECRUITING · started Apr 10, 2026ClinicalTrials.gov NCT07175441 · fetched Nov 12, 2026
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal CancerPHASE2 · RECRUITING · started Jan 17, 2025ClinicalTrials.gov NCT06824064 · fetched Nov 12, 2026
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsPHASE1 · RECRUITING · started Jul 11, 2022ClinicalTrials.gov NCT05270213 · fetched Nov 12, 2026
NIH awards1
- Inhibitors of ENPP1 for the treatment of hepatocellular carcinomaFiscal year 2025 · $306.7KNIH RePORTER 1R41CA302163-01 · fetched Nov 12, 2026